knowledge -WSS

knowledge

author：focus 2025-08-27 16:47:25 - browse：62

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Adele warns fans about throwing things at performers onstage

WSS

Suspect in Ukraine detonates explosives at a courthouse, killing himself and wounding 2 officers

Condition critical? Britain's beloved but battered National Health Service turns 75

Philadelphia mass shooting: Few answers in apparently random attack as suspect charged with murder

Gov. Ron DeSantis' push for 'civics' education: What does it look like?

Rivals hope for voter 'fatigue' as Trump's woes mount but base stays loyal: ANALYSIS

Lifetime voting ban for felony convictions struck down in Mississippi

focus

knowledge

leisure time

In Memoriam: Notable people who died in 2023

Jesse Tyler Ferguson makes friendship bracelets for Taylor Swift's Eras Tour

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Search warrant issued in 1996 disappearance of Kristin Smart

In Memoriam: Notable people who died in 2023

Pharma needs to include young adults in clinical research

Apple is now the first public company to be valued at $3 trillion

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

United colonoscopy coverage change 'may cost lives,' doctors say

Jailed Russian opposition leader Alexey Navalny gets 19 more years in prison

focus

Condition critical? Britain's beloved but battered National Health Service turns 75

Scientists find bacteria from stomach of ancient iceman

'Insanity': 4th of July mass shootings across US kill 13, injure more than 80

Accuser says Kevin Spacey grope wasn't a caress: ‘It was like a cobra ... angry’

Climate activists disrupt London Pride march to protest corporate sponsorship

China dismisses criticism of top diplomat's comments appearing to push for race

focus

focus

knowledge

hotspot